P3 Rett's result will not be known until (perhaps well into) 2021. 12 werks sounds little, but they screen (dunno what the criteria are, but they ARE). They want (as they see it) the best chance of success. Then there is the follow up study(ies). Drug approval won't come until (perhaps late) 2022 or even 2023 - assuming it actually gets there.
In the meantime, we need to progress 2951 - very costly and long, long time before we generate income - if at all.
My reading is Toreya endeavours are DITW - hence the 'corporate preso', looking for a cornerstone investor - hence the sudden rise from low $1's to mid $2's, for no announced reason(s) - big pump, but difficult to maintain momentum.
All's good, all's good as a risky investment, but the wait could be long, long (compared to the expectations of some) with funds needed to keep the dream alive.
Leave me out of the expected 'big things are around the corner'. It is going to be a long, tough slog, but the potential for a 'goose laying golden eggs' is a reward scenario still very much worth contemplating, but as a risk adjusted play, the market is not as stupid as some would like to think.
NEU Price at posting:
$2.29 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)